The Middle East Respiratory Syndrome (MERS) drugs in development market research report provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Middle East Respiratory Syndrome (MERS). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued products.

GlobalData tracks 71 drugs in development for Middle East Respiratory Syndrome (MERS) by 64 companies/universities/institutes. The top development phase for Middle East Respiratory Syndrome (MERS) is preclinical with 36 drugs in that stage. The Middle East Respiratory Syndrome (MERS) pipeline has 58 drugs in development by companies and 13 by universities/ institutes. Some of the companies in the Middle East Respiratory Syndrome (MERS) pipeline products market are: Dominari, LegoChem Biosciences and Regeneron Pharmaceuticals.

The key targets in the Middle East Respiratory Syndrome (MERS) pipeline products market include Middle East Respiratory Syndrome coronavirus S Protein (Spike Protein), 2019 Novel corona Virus Spike Glycoprotein (E2 or Peplomer Protein or S), and 3C Like Proteinase (3CL-PRO or 3CLp or EC 3.4.22.).

The key mechanisms of action in the Middle East Respiratory Syndrome (MERS) pipeline product include Middle East Respiratory Syndrome coronavirus S Protein (Spike Protein) Inhibitor with seven drugs in Phase I. The Middle East Respiratory Syndrome (MERS) pipeline products include nine routes of administration with the top ROA being Oral and 16 key molecule types in the Middle East Respiratory Syndrome (MERS) pipeline products market including Small Molecule, and Recombinant Vector Vaccine.

Middle East Respiratory Syndrome (MERS) overview

Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough, and shortness of breath. Other symptoms include nausea, vomiting, and diarrhea. Pneumonia is common, and organs damage can occur to the kidneys or other organs. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

For a complete picture of Middle East Respiratory Syndrome (MERS)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.